BioCentury | Jan 26, 2021
Regulation

Jan. 25 Quick Takes: Comirnaty approved in Australia, authorized in Hong Kong; plus Albireo, Iterum and AZ

Comirnaty (BNT162b2) from BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) received provisional approval from the Australian Therapeutic Goods Administration and emergency use authorization from the Food and Health Bureau of the Hong Kong Special Administrative Region...
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and hematological cancers. While...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

A pair of deals with Merck on Monday gives Seattle Genetics $1.7 billion in cash before counting any milestones, enough to bring additional cancer programs or ADC technologies into the fold via in-licensing...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New investors in the kidney disease company include...
BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...
BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

Jnana is developing small molecules against a relatively untapped class of proteins -- solute carriers -- to modulate cell metabolism. On Tuesday, the biotech closed its first deal with a large biopharma, partnering with Roche...
BioCentury | Jul 13, 2020
Targets & Mechanisms

Verge puts ALS target through COVID-19 paces, leaning on preclinical partners

After a drug repositioning screen flagged Verge’s ALS target PIKFYVE as an Achilles heel for COVID-19, the neurodegeneration-focused biotech jumped into infectious disease by tapping the growing ecosystem of partners with industrialized SARS-CoV-2 assays. That...
Items per page:
1 - 10 of 600